Patent ID: 11857605
Assignee: BILLION KING INTERNATIONAL LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 22:
23. The method of claim 21, wherein the thiol has the formula: R1SH or a pharmaceutically acceptable salt or zwitterion thereof, wherein R1 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or —(CR2),1Y, wherein n is an integer selected from 0-10; R for each instance is independently hydrogen, alkyl, aralkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two instances of R taken together form a 3-6 membered cycloalkyl or heterocycloalkyl containing 1, 2, or 3 heteroatoms selected from N, O, and S; and Y is selected from the group consisting of R1 is alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, aralkyl, heteroaryl, or —(CR2)nY, wherein n is an integer selected from 0-10; R for each instance is independently hydrogen, alkyl, aralkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two instances of R taken together form a 3-6 membered cycloalkyl or heterocycloalkyl containing 1, 2, or 3 heteroatoms selected from N, O, and S: and Y is selected from the group consisting of OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R4)2, —(NR4)(C═O)R4, —(NR4)(C═O)OR4, —O(C═O)N(R4)2, —O(C═N R4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R4)2, —OS(O)2R4, —(NR4)S(O)2R4, —OS(O)20R, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, —(NR4)S(O)20R4, and —(CRR2R3), wherein R2 is hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R4)2, —(NR4)(C═O)R4, —(NR4)(C═O)R4, —O(C═O)N(R4), —O(C═NR4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R)2—, —OS(O)2R4, —(NR4)S(O)2R, —OS(O)20R4, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, or —(NR4)S(O)2OR4; R3 is hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, OR4, SR4, N(R4)2, —(C═O)R4, —(C═O)OR4, —O(C═O)R4, —O(C═O)OR4, —(C═O)N(R′)2, —(NR4)C═O)R4, —(NR4)(C═O)OR4, —O(C═O)N(R4)2, —O(C═NR4)N(R4)2, —(NR4)(C═O)N(R4)2, —(C═NR4)N(R4)2, —(NR4)(C═NR4)N(R4)2, —(S═O)R4, —S(O)2R4, —S(O)2OR4, —S(O)2N(R4)2, —OS(O)2R4, —(NR4)S(O)2R4, —OS(O)20R4, —OS(O)2N(R4)2, —(NR4)S(O)2N(R4)2, or —(NR4)S(O)20R4; and
R4 for each instance is independently selected from the group consisting of hydrogen, alkyl, aralkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; or R1 is a moiety selected from the group consisting of:, N5-(1-((carboxymethyl)amino)-1-oxo-3K′-propan-2-yl)glutamine or a pharmaceutically acceptable salt thereof, wherein m is a whole number selected from 1-1000.